Tourmaline Bio (TRML) Competitors

IDEAYA Biosciences (NASDAQ:IDYA) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

Does the MarketBeat Community prefer IDYA or TRML?

IDEAYA Biosciences received 119 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 96.00% of users gave Tourmaline Bio an outperform vote while only 71.86% of users gave IDEAYA Biosciences an outperform vote.

Company	Underperform	Outperform
IDEAYA Biosciences	Outperform Votes 143 71.86%	Underperform Votes 56 28.14%
Tourmaline Bio	Outperform Votes 24 96.00%	Underperform Votes 1 4.00%

Which has higher valuation and earnings, IDYA or TRML?

Tourmaline Bio has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$7M	277.51	-$274.48M	-$3.59	-6.18
Tourmaline Bio	N/A	N/A	-$42.12M	-$3.21	-6.13

Is IDYA or TRML more profitable?

Tourmaline Bio's return on equity of -20.97% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-26.74%	-25.54%
Tourmaline Bio	N/A	-20.97%	-20.56%

Which has more volatility and risk, IDYA or TRML?

IDEAYA Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.

Do analysts rate IDYA or TRML?

IDEAYA Biosciences presently has a consensus price target of $54.27, suggesting a potential upside of 144.69%. Tourmaline Bio has a consensus price target of $49.33, suggesting a potential upside of 150.68%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tourmaline Bio is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tourmaline Bio	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders have more ownership in IDYA or TRML?

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media prefer IDYA or TRML?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 6 mentions for Tourmaline Bio. Tourmaline Bio's average media sentiment score of 1.49 beat IDEAYA Biosciences' score of 0.98 indicating that Tourmaline Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tourmaline Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tourmaline Bio beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks.